Protagonist Therapeutics, Inc (PTGX): Depreciation & Amortization
$1.28M
Year ended 2025-12-31
$1.54M
Trailing 12 months to 2026-06-30
+7.4%
3-year compound annual growth
+6.2%
5-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.28M | +55.0% | 2026-02-25, From 2025-01-01 |
| 2024-12-31 | $826.0K | -15.5% | 2026-02-25, From 2024-01-01 |
| 2023-12-31 | $977.0K | -5.5% | 2026-02-25, From 2023-01-01 |
| 2022-12-31 | $1.03M | +27.2% | 2025-02-21, From 2022-01-01 |
| 2021-12-31 | $813.0K | -14.2% | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | $948.0K | +29.5% | 2023-03-15, From 2020-01-01 |
| 2019-12-31 | $732.0K | n/c | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $527.0K | +29.8% | 2021-03-10, From 2018-01-01 |
| 2017-12-31 | $406.0K | +28.1% | 2020-03-10, From 2017-01-01 |
| 2016-12-31 | $317.0K | +28.3% | 2019-03-12, From 2016-01-01 |
| 2015-12-31 | $247.0K | -4.3% | 2018-03-07, From 2015-01-01 |
| 2014-12-31 | $258.0K | n/a | 2017-03-07, From 2014-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $1.28M | +55.0% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $1.60M | +14.3% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $548.0K | -23.7% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $4.15M | -15.4% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $1.54M | -6.3% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $24.0K | -97.1% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $621.0K | +16.3% |
| Biofrontera Inc. (BFRI) | 2025-12-31 | $138.0K | -67.2% |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $4.32M | +14.2% |
Compare PTGX, SEPN, AQST, CPIX side by side · Screen every company in Pharmaceutical Preparations ↗